25-OCT-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3789 270 170 99 42 5 02/06/2019 460 187
Screened at PD     1348 114 86 54 27 3      
Pre-Screened prior to PD     2430 145 76 41 14 2      
Treatment-naive     11 11 8 4 1 0      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     517 24 14 9 4 2      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     2006 259 244 73 34 7      
Screened at PD     1119 132 121 54 26 5      
Pre-Screened prior to PD     821 113 111 15 7 2      
Treatment-naive     11 11 9 4 1 0      
After PD on a Lung_MAP Sub-Study     55 3 3 0 0 0      
 
Sub-Study Assignments (open studies only)
S1800E     226 226 226 64 31 7      
S1900G     32 7 3 1 0 0      
S1900J     14 6 3 2 1 0      
S1900K     24 18 12 6 2 0      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     540 49 39 26 4 1      
Initial sub-study registrations     528 49 39 26 4 1      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1800E: Non-Match: Docetaxel + Ramu +/- Cemiplimab   378 27 27 27 21 3 1 05/22/2025 320 100
Docetaxel plus Ramucirumab Y   15 15 15 12 3 1      
Cemiplimab plus Docetaxel and Ramucirumab Y   12 12 12 9 0 0      
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 22 6 3 1 0 0 05/05/2023 288 106
Capmatinib + Osimertinib + Ramucirumab Y   12 5 2 1 0 0      
Capmatinib + Osimertinib Y   10 1 1 0 0 0      
S1900J: MET Amplification: Amivantamab Hyaluronidase   88 3 3 1 1 1 0 11/19/2024 206 75
Amivantamab Hyaluronidase Y   3 3 1 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 14 12 8 3 0 0 08/08/2024 268 91
Tepotinib + Ramucirumab Y   9 8 5 1 0 0      
Tepotinib Y   5 4 3 2 0 0